Document is current
Any future updates will be listed below
-
Authors
Daneels, Willem
Van Parys, Alexander
Huyghe, Leander
Rogge, Elke
De Rouck, Steffi
Christiaen, Ruben
Zabeau, Lennart
Taveirne, Sylvie
Van Dorpe, Jo
Kley, Niko
Cauwels, Anje
Depla, Erik
Tavernier, Jan
Offner, Fritz
-
Funding
Funding for this research was provided by:
Agentschap Innoveren en Ondernemen (Baekeland mandate (VLAIO - HBC.2021.0231))
Belgian Hematological Society (SAFYHR award 2021)
Vlaamse Overheid (Methusalem)
European Research Council (Advanced ERC (CYRE, N° 340941))
- License Information
-
More Information
Article History
Received: 19 June 2023
Accepted: 13 May 2024
First Online: 3 June 2024
Declarations
:
: Ethical approval for the development of PDX models, and the use of human cord blood, was obtained from the Ethics Committee of the Ghent University Hospital, Belgium<i> (</i>2018/0625—B670201836310 and BC-07613—B6702020000563). Written informed consent was obtained from all subjects before the study. Animal experiments followed the Federation of European Laboratory Animal Science Association (FELASA) guidelines and were approved by the Ethical Committee of Ghent University (ECD-19–01/19-10K). Samples were stored in the registered biobank “PDX Hematologie UZGent” (Belgian Registration number BB190094).
: JT, AC, AV, SD, ER, LZ, ED, RC, LH, NK and ST are currently employed by Orionis Biosciences. NK and JT hold equity interests in Orionis Biosciences and JT received financial research support from Orionis Biosciences. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
